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Abstract 
Impulse Control Disorders (ICDs) are a set of behaviours characterised by impulsivity despite 
known harm. Related to ICDs is the dopamine dysregulation syndrome (DDS), which is 
characterised by an addiction-like consumption of dopaminergic medication and punding. 
These behaviours all have an increased prevalence in Parkinson’s disease (PD). The aim of 
this review is to identify treatments available for patients suffering from ICDs, DDS and 
punding in PD. Searches of The Cochrane Controlled Trials Register, Embase, Medline and 
PsychInfo were conducted, using the entire timescale available. Seven out of the 688 papers 
retrieved met the inclusion criteria and were considered in this systematic review. One class I 
study, one class II study, and five class IV studies were identified. All studies demonstrated a 
positive effect on ICDs in PD. Research in this field is still in its early stages. At present, 
there is insufficient evidence to recommend any treatment over another. There is a need for 
more methodologically robust research, using larger, more generalizable samples, 
randomisation and meaningful follow-up periods. Additionally, the use of a validated 
outcome measures should be implemented in future research efforts.  
 
 
 
 
 
 
 
 
Key words: Impulse Control Disorders; Impulse-Compulsive Behaviours; Parkinson’s 
Disease; Systematic review; Treatment.  
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1. Introduction 
Parkinson’s disease (PD) is primarily a neurodegenerative disorder characterised by a loss of 
dopaminergic neurons in the nigrostriatal pathway, resulting in a classic repertoire of motor 
symptoms: i.e. bradykinesia, resting tremor, rigidity, and postural instability. These motor 
symptoms have long been the hallmark of both diagnosing and treating PD with treatment 
aimed at providing symptomatic relief by attempting to replace the lost dopamine. This is 
predominantly managed either with dopamine agonists or by using Levodopa, a dopamine 
precursor. Neurodegeneration of the nigrostriatal contributes to both motor and non-motor 
symptoms (e.g. sleep disorders, autonomic dysfunction, and neuro-endocrinal problems; 
Chaudhuri and Schapira, 2009; Politis et al., 2008). These symptoms can be broadly 
classified into neuropsychiatric problems (including disturbances in cognition and mood), 
sleep disturbances and autonomic symptoms. These non-motor symptoms commonly 
dominate the clinical picture in severe PD and, as such, have a significant impact on quality 
of life and disability (Rahman et al., 2008). The pathophysiology of these symptoms remains 
poorly understood. This, coupled with the emphasis placed on the motor symptomatology of 
PD, has led to the non-motor complications gaining a relatively late entry into the field of 
treatment research. Notwithstanding this, in the past few decades a greater emphasis has been 
placed on non-motor symptoms with new treatment avenues being identified (Wood et al., 
2010). 
1.1. Impulse-Compulsive Behaviours 
For the purpose of this review, Impulsive-Compulsive Behaviours (ICBs) will be used as an 
umbrella term to include Impulse Control Disorders (ICDs), Dopamine Dysregulation 
Syndrome (DDS) and punding. ICDs are defined as a set of behavioural disorders 
characterised by repetitive, maladaptive, and disinhibited behaviours that an individual 
engages in despite being aware of their potentially harmful consequences to the self or others 
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(Association, 2000). The most common ICDs in PD include pathological gambling (PG), 
hypersexuality (HS), compulsive eating (CE), compulsive buying (CB), kleptomania, 
trichotillomania (repetitive hair pulling), intermittent explosive behaviour (recurrent outbursts 
of aggression), and pyromania (deliberate fire-setting). DDS is characterised by a compulsive 
use of dopaminergic medication, in a similar manner to substance addiction (Giovannoni et 
al., 2000), dopaminergic medication hoarding, continual self-medication despite the onset of 
severe dyskinesia, and hypomania (Giovannoni et al., 2000). Punding is defined as a 
compulsive, repetitive, and purposeless behaviour (which the patient recognises as being 
meaningless), usually causing isolation, social withdrawal, and irritation for the individual 
when the behaviour is interrupted (Evans et al., 2004). 
 ICBs are common neuropsychiatric complications seen in PD. The DOMINION 
study, an epidemiological study looking at the incidence of ICBs in PD across movement 
disorder centres in USA and Canada, reported a prevalence of 13.6% compared to 1% in the 
general population (Ferris et al., 1996; Weintraub et al., 2010a). However, the actual 
incidence may be higher as a result of underreporting due to the stigma and shame attached to 
many of these behaviours (Weintraub et al., 2006).  
1.2. Pathophysiology 
The mechanism underlying the development of these behaviours has not been fully 
elucidated, although the use of dopamine agonists has been identified as a risk factor (Voon 
et al., 2006; Weintraub et al., 2010a) with studies showing the reversal of symptoms on 
dopamine agonist discontinuation (Mamikonyan et al., 2008). Additionally, several papers 
have identified associations between ICBs and polymorphisms of genes involved in 
metabolising dopamine and dopamine receptors, indicating a genetic predisposition to ICBs 
(Cormier et al., 2013; Eisenegger et al., 2010). Other risk factors for ICBs in PD include 
being male, developing PD at a younger age, having a personal or family history of addictive 
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behaviour, experiencing depressive symptoms, and having a novelty seeking personality 
(Pontone et al., 2006; Voon et al., 2006; Weintraub, 2009). 
 Despite the pathophysiology of ICBs in PD being unclear, the mesolimbic pathway of 
the brain has been implicated in its development (Cilia et al., 2008), along with the ventral 
striatum and prefrontal cortex, where alterations in the responsiveness to reward and 
punishment are thought to occur (Reuter et al., 2005).  
More recently, a bio-psycho-social model of ICBs has been proposed which purports 
that impulsive behaviours arise from maladaptive coping mechanisms to deal with the 
psychological distress of dealing with a chronic condition, especially in a younger population 
where the disability has a greater impact on quality of life (Delaney et al., 2012). In the 
proposed model, psychological distress predisposes patients to developing ICBs and 
dopamine agonists act to multiply the susceptibility to ICBs. If this is above a certain 
threshold, ICBs arise, offering an explanation as to why only a subset of patients are affected 
(Delaney et al., 2012). 
To date, no evidence-based method has been established for treating ICBs in PD. 
Management typically consists of dose reduction or discontinuation of dopamine agonists, 
which can be coupled with an increase in levodopa dose (Mamikonyan et al., 2008), however, 
there are several limitations to this approach. Firstly, care must be taken to balance 
ameliorating the ICB symptoms with preventing an increase in motor symptoms. Dopamine 
agonists have been established as an effective treatment for the motor symptoms of PD 
(Stowe et al., 2008) and therefore staying on the treatment takes precedent over a non-
evidence based method of tackling ICBs. Secondly, abrupt cessation or dose reduction of 
dopamine agonists can lead to the development of a dopamine agonist withdrawal syndrome 
(DAWS; Limotai et al., 2012). DAWS is defined as a group of symptoms, both physiological 
and psychological, resembling those of other drug withdrawal syndromes. Symptoms such as 
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dysphoria, anxiety, and drug cravings are present and have been shown to occur in a drug-
dependent manner (Pondal et al., 2013). Additionally, the cravings present can lead to 
hesitation on the patient’s behalf in stopping treatment despite the ongoing ICBs and 
dyskinesia present with excessive use (Rabinak and Nirenberg, 2010). Furthermore, despite 
treatment reduction and switching to Levodopa, some patients remain drug refractory and 
ICBs prevail (Ávila et al., 2011; Bermejo, 2008a; Kurlan, 2004), indeed levodopa has been 
identified as a causatory agent (Ávila et al., 2011). The significant impact of ICBs on a 
patient’s quality of life gives rise to the need for treatment without these limitations (Leroi et 
al., 2011; Nikitina et al., 2013). The aim of this review is to track progress towards an 
evidence-based treatment for ICBs in PD and to identify future research needs. 
2. Methods 
This systematic review was conducted at Institute of Psychiatry, King’s College London, UK 
using studies retrieved by performing electronic searches of the Cochrane controlled trials 
register, MEDLINE, EMBASE, and PsychInfo, along with the references of identified 
papers. The entire timescale was used up to February 2014 (week 8) inclusive. 
 The search strategy employed the following keywords: “Parkinson’s Disease” and 
“Impulse Control Disorders” or “Dopamine Dysregulation Syndrome” or “DDS” or 
“punding”, in combination with “management” or “treatment” or “therapeutics” or “CBT” or 
“pharmacological therapy” or “drug therapy” or “pharmacological interventions”. The 
inclusion criteria were studies: (1) investigating at the effectiveness of any type of treatment 
on for impulse control disorders in PD; (2) with participants presenting a clinical diagnosis of 
idiopathic PD currently on medication for PD, including all genders and ages; (3) with 
participants with no co-morbidities such as dementia (MMSE>24), psychosis, or any other 
neuropsychiatric complications; (4) assessing treatment according to DSM-IV criteria 
(American Psychiatric Association, 1994) or using a validated outcome measure; and (5) 
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utilising all methodological designs (where full-text was available). The exclusion criteria 
were studies carried out on animals, not available in English, or with retrospective data 
analysis (i.e. studies needed to be testing an active treatment with the aim of reducing ICBs). 
Initially titles were screened and duplicates were excluded. The remaining abstracts 
were screened and studies were excluded using the inclusion/exclusion criteria. After the first 
screening, the remaining full text articles were assessed against a quality checklist in 
consideration of selection, performance, detection, attrition and reporting biases. The 
following details were collected from each study: bibliographic details (i.e. author, country, 
and date of study); design of study; number of participants; mean participant age; percentage 
of male patients; method of assessing ICBs; type of treatment; outcome measures; average 
follow-up period; methods of statistical analysis; findings and conclusions of authors (see 
Table 1). 
3. Results 
Six hundred and eighty eight studies were retrieved through the search strategy. Of these, 124 
were duplicates and 530 were excluded on abstract review because inclusion/exclusion 
criteria [studies done on animals (12), not in English (six), not dealing with the clinical 
condition (178), not looking at treatment of the clinical condition (162) and literature reviews 
(171)]. 34 full-text studies were read and further assessed for eligibility (inclusion/exclusion 
criteria). These were also subjected to a quality checklist (described above). Twenty seven 
studies were excluded (10 based on the exclusion criteria and 17 as a result of the quality 
checklist). Seven studies were included in this systematic review.  
3.1. Pharmacological Treatment 
One class I and five class IV trials were identified that evaluated pharmacological treatments 
for ICBs. All the pharmacological agents reviewed demonstrated positive effects on reduction 
of ICBs. The class I trial was a double blind RCT looking at the effect of 200mg/day 
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Amantadine against placebo control lasting 17 weeks and included 17 patients with 
pathological gambling (Thomas et al., 2010). A combination crossover and open label design 
was used, with patients switching from intervention to control group (and vice versa) after 
two weeks of treatment (with a one week washout period in between) before a final stage 
where all patients were put on active treatment for two weeks. All patients showed a 
reduction in pathological gambling behaviour, measured using the Yale-Brown Obsessive 
Compulsive Scale (Y-BOCS; Goodman et al., 1989) and the Gambling Symptom Assessment 
Scale (G-SAS; Kim et al., 2009).  
 Emilio Bermejo et al. (2010) reported positive effects of 200mg/day of Zonisamide 
(an anticonvulsant) on ICBs, assessed using the Barratt Impulsiveness Scale (BIS; Patton and 
Stanford, 1995) and the Clinical Global Impression (CGI; Guy, 1976). A decrease in both 
outcome measures was reported (statistical significance was not reported) with a marginal 
change in motor symptoms. Adverse events were reported in four patients (26%) and one 
patient dropped out due to lack of effectiveness.  
 The remaining studies were small case reports (n≤4) and looked at various drugs: 
Finasteride (Bortolato et al., 2012), Naltrexone (Bosco et al., 2012), Clozapine (Hardwick et 
al., 2013) and Valproate (Sriram et al., 2013). All the case reports demonstrated an 
improvement in ICB symptomatology using a variety of outcome measures.  
3.2. Psycho-social Treatment 
The single class II trial that used a psycho-social treatment for the management of ICDs in 
PD identified was a RCT that featured 45 patients (Okai et al., 2013). Twenty-eight patients 
were assigned to an intervention group that consisted of 12 sessions of nurse-led Cognitive-
Behavioural Therapy (CBT) and standard medical care, comprising of psycho-education (e.g. 
the provision of leaflets about treatment and adverse effects) and continual review by the 
multi-disciplinary team. The control group received standard medical care only. ICBs were 
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initially screened for using the Questionnaire for Impulsive-Compulsive Disorders in 
Parkinson’s disease (QUIP; Weintraub et al., 2009b), and diagnoses subsequently made 
following a clinical interview using the DSM-IV criteria for ICDs (American Psychiatric 
Association, 1994). Results revealed a statistically significant decrease in ICBs (p=0.002) and 
a decrease in overall severity of symptoms (p=0.004) following the CBT intervention, which 
were assessed using the Impulse Control Behaviour Severity Scale (ICBSS; developed by the 
study authors) and CGI respectively.  
4. Discussion 
All treatments included in this review demonstrated an amelioration of ICB symptomatology 
but research is nascent. Good quality studies looking at the treatment of ICBs in PD are 
scarce, especially those evaluating CBT. Case studies are rich in descriptive data but can be 
subject to bias (particularly selection bias), which significantly decreases the generalizability 
of results.  
Although the results from the RCT looking at CBT were positive, care must be taken 
with its interpretation. For example, the study utilised a validated measure for screening for 
ICBs but a study-author generated tool to assess the effect of treatment, for which little data 
exists to assess its psychometric properties. Furthermore, there was a relatively high dropout 
rate in the study, with only 58% of patients in the intervention group completing all sessions. 
No adverse events were reported, however no reason was given for the high dropout rate and 
no intention-to-treat analysis was conducted either. A post-hoc analysis would be useful 
adjunct to such studies to assess reasons for drop-out because CBT is a promising avenue to 
explore, especially because it does not risk interaction effects with Levodopa or dopamine 
agonists, that is present with pharmacological treatments for ICBs. One reason for the low 
compliance could be due to mobility issues in PD, especially severe PD, so options looking at 
alternative delivery for psychosocial treatment could potentially be pursued. 
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 Amantadine is an NMDA receptor antagonist which is currently used in PD to 
decrease the dyskinesia produced by Levodopa (Luginger et al., 2000). The trial looking at 
amantadine demonstrated a statistically significant decrease in ICBs and was 
methodologically sound. However, it had a very short follow-up period (4 weeks) and, 
similarly to the CBT trial, had a high dropout rate (29%). This was due to adverse events, 
notably reports of hallucinations and confusion. Additionally, the effects were very short-
lived and consequently, in the washout period, an increase in gambling scores was seen after 
just one week. 
 A post-hoc analysis of a large multi-centred epidemiological study showed a 
significant association between amantadine use and ICBs (17.6% of patients on amantadine 
vs. 12.4% of those not on amantadine) (Weintraub et al., 2010b). More studies are necessary 
to determine the exact effect amantadine has on ICBs because it is already used in PD and is 
known to have a beneficial effect on motor symptomatology. Future studies should also 
determine whether the side effects of amantadine are tolerable in this already debilitated 
population. 
 Zonisamide (a sulphonamide anticonvulsant) and Naltrexone (an opioid receptor 
antagonist), Clozapine (an antipsychotic) and Valproate were all effective at treating ICBs, 
However, all the studies evaluating these pharmaceutical agents have been small and without 
controls. Larger studies with higher methodological qualities are needed to more thoroughly 
establish efficacy. A large-scale double-blind RCT has been conducted that investigates the 
effect of naltrexone on ICBs in PD, however it has not yet been published so the results are 
unavailable (Weintraub, 2013). 
The range of ICBs (ICDs, DDS, punding, etc.) in PD makes selection of a validated 
outcome that can assess the associated behaviours problematic. For some ICDs, like PG, 
specific and validated outcomes measures are available, whereas for the less common ICDs 
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and DDS the authors could not identify a disorder-specific validated scale. One study resorted 
to using non-specific measures like the CGI in combination with the BIS (Bermejo, 2008b), 
which was not designed for PD population. However, the QUIP has been shown to have both 
high sensitivity and selectivity with regards to ICBs (regardless of whether it is completed by 
the patient or a carer) and a rating scale (QUIP-RS) has just been devised (Weintraub et al., 
2009a; Weintraub and Siderowf, 2012). An advantage of the QUIP is that it encompasses 
ICDs, DDS, and punding, and has been developed specifically for patients with PD. Although 
it was created in 2009, none of the studies reviewed here used it as an outcome measure. 
Deep Brain Stimulation (DBS) has also been implicated in ICBs in PD, with some 
suggestion that DBS may induce ICBs (Halbig et al., 2009). However, because patients who 
have undergone DBS can reduce their dopaminergic medication, DBS can lead to a reduction 
in ICBs (Demetriades et al., 2011). A recent review (Demetriades et al., 2011) identified four 
studies and 37 case reports investigating the role of DBS in ICBs. The review concluded that 
the nature of the relationship between DBS and ICBs is unclear. None of the studies that were 
identified in this review met our inclusion/exclusion criteria because the primary intention of 
DBS was not to reduce ICBs. 
 Currently there is insufficient evidence to support or refute the effectiveness of the 
aforementioned treatments in improving ICBs in PD. The research is still in its early stages 
and although positive results have been obtained for all the studies included in this review, 
the studies are generally small and lacking controls. Furthermore, only one study has been 
carried out for each treatment. However, these studies act as stepping-stones to direct future 
research. The use of a standardised outcome measure should be implemented when 
conducting research in this field. Questionnaires such as the QUIP or QUIP-RS could be 
used, which have been specifically designed for ICBs in PD and have been shown to have 
high sensitivity for the detection of ICBs in this population. 
Running Head: TREATMENTS FOR ICDS IN PARKINSON’S DISEASE 
 
 
 
12 
 
Acknowledgements 
Author BAF receives salary support from the National Institute for Health Research (NIHR) 
Mental Health Biomedical Research Centre and Dementia Research Unit at South London 
and Maudsley NHS Foundation Trust and King’s College London. The views expressed are 
those of the author and not necessarily those of the NHS, the NIHR or the Department of 
Health. 
 
Conflict of Interest 
Puja Tanwani, Bruce A. Fernie, Ana V. Nikčević and Marcantonio M. Spada declared that 
they have no conflict of interest. 
 
 
 
 
 
 
 
 
 
 
 
References 
Running Head: TREATMENTS FOR ICDS IN PARKINSON’S DISEASE 
 
 
 
13 
American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders: 
DSM-IV-TR®. American Psychiatric Pub. 
Ávila, A., Cardona, X., Martín-Baranera, M., Bello, J., Sastre, F., 2011. Impulsive and compulsive 
behaviors in Parkinson's disease: A one-year follow-up study. Journal of the Neurological Sciences 
310, 197-201. 
Bermejo, P.E., 2008a. Topiramate in managing impulse control disorders in Parkinson's disease. 
Parkinsonism and Related Disorders 14, 448-449. 
Bermejo, P.E., 2008b. Topiramate in managing impulse control disorders in Parkinson's disease. 
Parkinsonism and Related Disorders 14, 448-449. 
Bortolato, M., Cannas, A., Solla, P., Bini, V., Puligheddu, M., Marrosu, F., 2012. Finasteride 
attenuates pathological gambling in patients with Parkinson disease. Journal of Clinical 
Psychopharmacology 32, 424-425. 
Bosco, D., Plastino, M., Colica, C., Bosco, F., Arianna, S., Vecchio, A., Galati, F., Cristiano, D., 
Consoli, A., Consoli, D., 2012. Opioid antagonist naltrexone for the treatment of pathological 
gambling in Parkinson disease. Clinical Neuropharmacology 35, 118-120. 
Chaudhuri, K., Schapira, A.H., 2009. Non-motor symptoms of Parkinson's disease: dopaminergic 
pathophysiology and treatment. The Lancet Neurology 8, 464-474. 
Cilia, R., Siri, C., Marotta, G., Isaias, I.U., De Gaspari, D., Canesi, M., Pezzoli, G., Antonini, A., 
2008. Functional abnormalities underlying pathological gambling in Parkinson disease. Archives of 
Neurology 65, 1604-1611. 
Cormier, F., Muellner, J., Corvol, J.C., 2013. Genetics of impulse control disorders in Parkinson's 
disease. Journal of Neural Transmission 120, 665-671. 
Delaney, M., Leroi, I., Simpson, J., Overton, P.G., 2012. Impulse control disorders in Parkinson's 
disease: a psychosocial perspective. Journal of Clinical Psychology in Medical Settings 19, 338-346. 
Demetriades, P., Rickards, H., Cavanna, A.E., 2011. Impulse control disorders following deep brain 
stimulation of the subthalamic nucleus in Parkinson's disease: clinical aspects. Parkinson's Disease 
2011. 
Running Head: TREATMENTS FOR ICDS IN PARKINSON’S DISEASE 
 
 
 
14 
Eisenegger, C., Knoch, D., Ebstein, R.P., Gianotti, L.R., Sándor, P.S., Fehr, E., 2010. Dopamine 
receptor D4 polymorphism predicts the effect of L-DOPA on gambling behavior. Biological 
Psychiatry 67, 702-706. 
Emilio Bermejo, P., Ruiz-Huete, C., Anciones, B., 2010. Zonisamide in managing impulse control 
disorders in Parkinson's disease. Journal of Neurology 257, 1682-1685. 
Evans, A.H., Katzenschlager, R., Paviour, D., O'Sullivan, J.D., Appel, S., Lawrence, A.D., Lees, A.J., 
2004. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Movement 
Disorders 19, 397-405. 
Ferris, J.A., Stirpe, T., Ialomiteanu, A., 1996. Gambling in Ontario: a report from a general population 
survey on gambling-related problems and opinions. Addiction Research Foundation, Problem and 
Compulsive Gambling Project. 
Friedman, J.H., 1994. Punding on levodopa. Biological Psychiatry 36, 350-351. 
Giovannoni, G., O'sullivan, J., Turner, K., Manson, A., Lees, A., 2000. Hedonistic homeostatic 
dysregulation in patients with Parkinson's disease on dopamine replacement therapies. Journal of 
Neurology, Neurosurgery & Psychiatry 68, 423-428. 
Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Fleischmann, R.L., Hill, C.L., Heninger, 
G.R., Charney, D.S., 1989. The Yale-Brown obsessive compulsive scale: I. Development, use, and 
reliability. Archives of General Psychiatry 46, 1006-1011. 
Guy, W., 1976. Clinical global impression scale. The ECDEU Assessment Manual for 
Psychopharmacology-Revised. Volume DHEW Publ No ADM 76 338, 218-222. 
Halbig, T.D., Tse, W., Frisina, P.G., Baker, B.R., Hollander, E., Shapiro, H., Tagliati, M., Koller, 
W.C., Olanow, C.W., 2009. Subthalamic deep brain stimulation and impulse control in Parkinson's 
disease. European Journal of Neurology 16, 493-497. 
Hardwick, A., Ward, H., Hassan, A., Romrell, J., Okun, M.S., 2013. Clozapine as a potential 
treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease. 
Neurocase 19, 587-591. 
Kim, S.W., Grant, J.E., Potenza, M.N., Blanco, C., Hollander, E., 2009. The Gambling Symptom 
Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Research 166, 76-84. 
Running Head: TREATMENTS FOR ICDS IN PARKINSON’S DISEASE 
 
 
 
15 
Kurlan, R., 2004. Disabling repetitive behaviors in Parkinson's disease. Movement Disorders 19, 433-
437. 
Leroi, I., Ahearn, D.J., Andrews, M., McDonald, K.R., Byrne, E.J., Burns, A., 2011. Behavioural 
disorders, disability and quality of life in Parkinson's disease. Age & Ageing 40, 614-621. 
Limotai, N., Oyama, G., Go, C., Bernal, O., Ong, T., Moum, S.J., Bhidayasiri, R., Foote, K.D., 
Bowers, D., Ward, H., 2012. Addiction-like manifestations and Parkinson's disease: a large single 
center 9-year experience. International Journal of Neuroscience 122, 145-153. 
Luginger, E., Wenning, G., Bösch, S., Poewe, W., 2000. Beneficial effects of amantadine on L‐dopa‐
induced dyskinesias in Parkinson's disease. Movement Disorders 15, 873-878. 
Mamikonyan, E., Siderowf, A.D., Duda, J.E., Potenza, M.N., Horn, S., Stern, M.B., Weintraub, D., 
2008. Long‐term follow‐up of impulse control disorders in Parkinson's disease. Movement Disorders 
23, 75-80. 
Nikitina, M., Zhukova, I., Izhboldina, O., Zhukova, N., Alifirova, V., Agasheva, A., Povalyaev, A., 
Titova, M., 2013. Influence of impulse control disorders on the quality of life among cognitively-
intact Parkinson's disease patients living in the Tomsk region, Russia. Journal of Parkinson's Disease 
3, 100-101. 
Okai, D., Askey-Jones, S., Samuel, M., O'Sullivan, S.S., Chaudhuri, K., Martin, A., Mack, J., Brown, 
R.G., David, A.S., 2013. Trial of CBT for impulse control behaviors affecting Parkinson patients and 
their caregivers. Neurology 80, 792-799. 
Patton, J.H., Stanford, M.S., 1995. Factor structure of the Barratt impulsiveness scale. Journal of 
Clinical Psychology 51, 768-774. 
Phillips, B., Ball, C., Sackett, D., Badenoch, D., Straus, S., Haynes, B., Oxford Centre for Evidence-
based Medicine levels of evidence (March 2009). Centre for Evidence Based Medicine Web site. 
Politis, M., Piccini, P., Pavese, N., Koh, S.-B., Brooks, D.J., 2008. Evidence of dopamine dysfunction 
in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study. 
Experimental Neurology 214, 112-116. 
Running Head: TREATMENTS FOR ICDS IN PARKINSON’S DISEASE 
 
 
 
16 
Pondal, M., Marras, C., Miyasaki, J., Moro, E., Armstrong, M.J., Strafella, A.P., Shah, B.B., Fox, S., 
Prashanth, L., Phielipp, N., 2013. Clinical features of dopamine agonist withdrawal syndrome in a 
movement disorders clinic. Journal of Neurology, Neurosurgery & Psychiatry 84, 130-135. 
Pontone, G., Williams, J.R., Bassett, S.S., Marsh, L., 2006. Clinical features associated with impulse 
control disorders in Parkinson disease. Neurology 67, 1258-1261. 
Rabinak, C.A., Nirenberg, M.J., 2010. Dopamine agonist withdrawal syndrome in Parkinson disease. 
Archives of Neurology 67, 58-63. 
Rahman, S., Griffin, H.J., Quinn, N.P., Jahanshahi, M., 2008. Quality of life in Parkinson's disease: 
the relative importance of the symptoms. Movement Disorders 23, 1428-1434. 
Reuter, J., Raedler, T., Rose, M., Hand, I., Gläscher, J., Büchel, C., 2005. Pathological gambling is 
linked to reduced activation of the mesolimbic reward system. Nature Neuroscience 8, 147-148. 
Sriram, A., Ward, H.E., Hassan, A., Iyer, S., Foote, K.D., Rodriguez, R.L., McFarland, N.R., Okun, 
M.S., 2013. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's 
disease. Journal of Neurology 260, 521-527. 
Stowe, R., Ives, N., Clarke, C., Van Hilten, J., Ferreira, J., Hawker, R., Shah, L., Wheatley, K., Gray, 
R., 2008. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev 2. 
Thomas, A., Bonanni, L., Gambi, F., Di Iorio, A., Onofrj, M., 2010. Pathological gambling in 
Parkinson disease is reduced by amantadine. Annals of Neurology 68, 400-404. 
Voon, V., Hassan, K., Zurowski, M., Duff-Canning, S., De Souza, M., Fox, S., Lang, A., Miyasaki, J., 
2006. Prospective prevalence of pathologic gambling and medication association in Parkinson 
disease. Neurology 66, 1750-1752. 
Weintraub, D., 2009. Impulse control disorder: Prevalence and possible risk factors. European 
Neuropsychopharmacology 19, S196-S197. 
Weintraub, D., Hoops, S., Shea, J.A., Lyons, K.E., Pahwa, R., Driver-Dunckley, E.D., Adler, C.H., 
Potenza, M.N., Miyasaki, J., Siderowf, A.D., Duda, J.E., Hurtig, H.I., Colcher, A., Horn, S.S., Stern, 
M.B., Voon, V., 2009a. Validation of the questionnaire for impulsive-compulsive disorders in 
Parkinson's disease. Movement Disorders 24, 1461-1467. 
Running Head: TREATMENTS FOR ICDS IN PARKINSON’S DISEASE 
 
 
 
17 
Weintraub, D., Hoops, S., Shea, J.A., Lyons, K.E., Pahwa, R., Driver‐Dunckley, E.D., Adler, C.H., 
Potenza, M.N., Miyasaki, J., Siderowf, A.D., 2009b. Validation of the questionnaire for impulsive‐
compulsive disorders in Parkinson's disease. Movement Disorders 24, 1461-1467. 
Weintraub, D., Koester, J., Potenza, M.N., Siderowf, A.D., Stacy, M., Voon, V., Whetteckey, J., 
Wunderlich, G.R., Lang, A.E., 2010a. Impulse control disorders in Parkinson disease: a cross-
sectional study of 3090 patients. Archives of Neurology 67, 589-595. 
Weintraub, D., Siderowf, A., 2012. Frequency of impulse control disorder symptoms in de novo 
Parkinson's disease patients and healthy controls. Movement Disorders 27, S291. 
Weintraub, D., Siderowf, A.D., Potenza, M.N., Goveas, J., Morales, K.H., Duda, J.E., Moberg, P.J., 
Stern, M.B., 2006. Association of dopamine agonist use with impulse control disorders in Parkinson 
disease. Archives of Neurology 63, 969-973. 
Weintraub, D., Sohr, M., Potenza, M.N., Siderowf, A.D., Stacy, M., Voon, V., Whetteckey, J., 
Wunderlich, G.R., Lang, A.E., 2010b. Amantadine use associated with impulse control disorders in 
Parkinson disease in cross‐sectional study. Annals of Neurology 68, 963-968. 
Weintraub, D., Xie, S.X., Stern, M., Hurtig, H., Siderowf, A., Minger, J., et al, 2013. Randomized, 
double-blind, placebo-controlled study of naltrexone for impulse control disorders in Parkinson's 
disease [abstract], Movement Disorders, p. 393. 
Wood, L.D., Neumiller, J.J., Setter, S.M., Dobbins, E.K., 2010. Clinical review of treatment options 
for select nonmotor symptoms of Parkinson's disease. The American Journal of Geriatric 
Pharmacotherapy 8, 294-315. 
 
 
Running Head: TREATMENTS FOR ICDS IN PARKINSON’S DISEASE 
 
 
 
18 
Table 1: Summary of studies retrieved of treatment for ICBs in patients with PD arranged according to type of study. 
First author  
Publication 
year 
 
Class 
(Philli
ps et 
al.) 
 
Design Intervention 
 
 
ICB type 
ICD 
/DDS/ 
Punding  
Sample demographics 
Completing number 
mean age 
% male 
Assessments after 
baseline 
Outcome 
measures 
 
 
Outcomes  
 
Limitations 
Bini, 2012 
 
IV Interventional 
Case report 
Finasteride 
5mg/day 
 
 
PG 
 
 
 
 
N=2 
59.0 years 
100% 
a) 2 week follow-up  
b) Monitored for mean 
of 10.5 months 
PG-YBOCS Reduction in PG after 2 
weeks  
 
Uncontrolled, 
open label, 
small sample 
size, cannot 
generalise 
Bermejo, 2010 IV Interventional 
Case series 
Zonisamide  
titrated up to 
200mg/day 
 
ICDs 
 
 
 
 
N=15 
62.1 years 
60% 
a) 2 month 
 follow-up 
b) 4 month 
 follow-up 
CGI 
BIS 
 
Resolution of behaviours in 
patients  
 
Adverse events in 4 patients 
(26%) 
Uncontrolled 
open label, 
small sample, 
cannot 
generalise 
Bosco, 2012 
 
IV 
 
Interventional 
Case report  
Naltrexone 
50mg/day 
PG N=3 
46.0 years 
100% 
 
a) 4 week follow up 
b) monitored    
    between 
    9.5 m – 13 m 
DSM-IV-TR 
criteria 
67% full remission of PG 
33% partial remission  
Uncontrolled, 
open label, 
small sample 
size, cannot 
generalise 
Hardwick, 2013 
 
IV Interventional 
Case report 
Clozapine: 
25mg/day on 
average  
 
Punding 
 
 
 
N=3 
61.9 years  
100% 
Average follow-up: 
3.9 years 
DSM-IV criteria, 
punding 
diagnosis: criteria 
published by 
Friedman et al. 
((Friedman, 1994) 
100% remission of punding 
behaviour 
Uncontrolled, 
open label, 
small sample 
size, cannot 
generalise 
Okai, 2013 
 
II 
 
Interventional 
RCT: 
A. CBT 
B. Standard medical 
care 
12 sessions of 
nurse-led 
CBT + 
standard 
medical care 
OR standard 
medical care 
on its own 
 
 
 
ICDs 45 (28 intervention) 
mean age: 
intervention:59.3±8.1 
control: 57.9 ± 9.5 
male sex: 
Intervention:19 (67.9)  
control- 12 (70) 
6 months  CGI 
NPI 
ICBSS 
Statistically significant 
reduction in ICDs using 
various outcome measures: 
CGI: 
0.004 (p-value)         
0.21 (effect size) 
NPI: 
0.033 (p-value) 
0.12 (effect size) 
ICBSS:  
0.020 (p value) 
0.18  (effect size) 
ICBSS to 
monitor change 
in ICD severity 
is not a 
standardised 
measure  
no blinding  
no intention to 
treat analysis 
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Sriram, 2013 
 
IV Interventional 
Case series 
Valproate 
extended 
release 
(average 
562.5mg/day) 
DDS N=4 
62.3 years  
50% 
a) follow-up 3-6m 
mean follow-up: 
5m 
Giovannoni 
criteria for DDS 
((Giovannoni et 
al., 2000) 
Symptoms resolved in all 
patients 
Small number, 
no standardised 
measure used, 
¾ had DBS 
which has been 
implicated in 
managing and 
causing ICDs 
Tomas, 2013 
  
I Interventional 
Double-blind 
crossover RCT 
A. amantadine 
    200mg/day 
B. placebo 
 
17weeks 
Amantadine 
200mg/day 
 
 
 
 
 
 
 
 
PG N=17 (12 completed) 
61.0 ± 1.6 years  
76.5% 
a) 4 week follow-up DSM-IV criteria  
G-SAS 
PG-YBOCS  
+daily diary 
entries 
 
Statistically significant 
reduction in all outcome 
measures: 
G-SAS and PG-YBOCS 
(p<0.001) 
 
5 patients dropped out due to 
adverse events (hallucinations 
and confusion)  
Short study 
duration, 
small sample 
size 
Abbreviations: ICDs: Impulsive-Compulsive Disorders; DDS: Dopamine Dysregulation Syndrome; PG: Pathological Gambling; RCT: Randomised-Control Trial; CBT: 
Cognitive-Behavioural Therapy; PRS: Punding Rating Scale; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition; CGI: Clinical Global 
Impression; NPI: Neuropsychiatric Inventory; ICBSS: Impulse Control Behaviour Severity Scale; MMSE: Mini-Mental State Examination; G-SAS: Gambling Symptom 
Assessment Scale; PG-YBOCS: Yale-Brown Obsessive Compulsive Scale modified for Pathological Gambling. 
 
 
